Ensartinib Market Report 2025

The ensartinib market size has grown rapidly in recent years. It will grow from $0.97 billion in 2024 to $1.09 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth observed during the historic period can be linked to favorable reimbursement decisions, expanded payer coverage for targeted lung cancer therapies, growth in early diagnosis initiatives, rising awareness among patients and clinicians of the benefits of targeted therapies, and increased emphasis on personalized medicine.

The ensartinib market size is expected to see rapid growth in the next few years. It will grow to $1.65 billion in 2029 at a compound annual growth rate (CAGR) of 11%. The growth projected for the forecast period can be attributed to continued expansion of biomarker screening, rising prevalence of non-small cell lung cancer, increasing demand for targeted cancer therapies, growing adoption of outcome-based treatment models, and heightened focus on patient convenience. Key trends during the forecast period include advancements in diagnostic techniques, AI-enabled trial matching, strategic collaborations with research institutions and healthcare providers, development of combination therapies, and increased investment in research and development.

The rising number of lung cancer cases is expected to drive the growth of the ensartinib market. Lung cancer is a condition where abnormal cells in the lungs multiply uncontrollably, often forming tumors that disrupt breathing and may spread to other body parts. Prolonged exposure to air pollution, especially fine particulate matter, contributes to the increasing incidence of lung cancer by gradually damaging lung tissue. Ensartinib treats lung cancer by inhibiting the abnormal activity of the ALK gene, which regulates tumor growth in patients with ALK-positive non-small cell lung cancer. For example, data from the Centers for Disease Control and Prevention (CDC) shows that new lung cancer cases in the United States rose from 218,893 in 2022 to 238,340 in 2023. This growing prevalence of lung cancer is driving the expansion of the ensartinib market.

The rise in healthcare spending is expected to further fuel the growth of the ensartinib market. Healthcare expenditure refers to the total amount spent by individuals, organizations, or governments on medical services, public health initiatives, medications, and related activities. As the population ages and requires more specialized care, healthcare spending continues to rise, leading to increased overall costs. This spending supports the availability of advanced cancer treatments such as ensartinib, helping ensure they are accessible in medical facilities. For instance, the American Medical Association reported that health spending in the U.S. grew by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per person, a significant increase compared to the 4.6% growth in 2022. This rising healthcare expenditure plays a key role in expanding the ensartinib market.

Leading companies in the ensartinib market are concentrating on gaining regulatory approvals to improve patient access in major global markets and secure expanded indications for treating additional ALK-positive NSCLC cases. Regulatory approvals are granted by health authorities once a drug demonstrates its safety, efficacy, and quality. For example, in December 2024, Xcovery Holdings, Inc. received FDA approval for ensartinib (branded as Ensacove) to treat adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not been previously treated with an ALK inhibitor. This approval was based on the phase 3 eXALT3 trial, which showed that ensartinib significantly improved progression-free survival compared to crizotinib (25.8 months vs 12.7 months), although overall survival rates were similar between the two groups. Ensartinib, a second-generation ALK inhibitor, targets abnormal ALK proteins and can overcome resistance, though it has side effects such as rash, muscle pain, constipation, cough, itching, nausea, swelling, fever, and fatigue.

Major players in the ensartinib market are Xcovery Holdings Inc., Betta Pharmaceuticals Co. Ltd.

North America was the largest region in the ensartinib market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ensartinib report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ensartinib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Ensartinib is a targeted cancer therapy available in oral or injectable forms that acts as a tyrosine kinase inhibitor. It specifically blocks the activity of the anaplastic lymphoma kinase (ALK) protein, which contributes to the uncontrolled growth and spread of certain cancer cells. Ensartinib is primarily prescribed for patients with ALK-positive non-small cell lung cancer, particularly those who have developed resistance or intolerance to earlier-generation ALK inhibitors, helping to slow tumor progression and improve clinical outcomes.

The main drug types of ensartinib include oral and injectable formulations. Oral ensartinib is administered by mouth, typically as tablets or capsules. It is used across different patient demographics, including pediatric, adult, and geriatric populations, for indications such as non-small cell lung cancer (NSCLC), other lung cancers, and potential new therapeutic applications. Treatment lines include first-line, second-line, and third-line or later therapy. Key end users include hospitals, specialty clinics, and other healthcare providers.

The ensartinib market research report is one of a series of new reports that provides ensartinib market statistics, including the ensartinib industry's global market size, regional shares, competitors with an ensartinib market share, detailed ensartinib market segments, market trends and opportunities, and any further data you may need to thrive in the ensartinib industry. This Ensartinib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ensartinib market consists of sales of ensartinib capsules, tablets, liquid formulations, prefilled syringes, and lyophilized powder. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.